Design Therapeutics (NASDAQ:DSGN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Design Therapeutics Trading Down 0.4 %
Shares of DSGN stock opened at $4.70 on Friday. The firm has a market capitalization of $266.12 million, a PE ratio of -5.53 and a beta of 1.77. The firm has a fifty day simple moving average of $4.76 and a two-hundred day simple moving average of $5.35. Design Therapeutics has a 12 month low of $2.45 and a 12 month high of $7.77.
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Stories
- Five stocks we like better than Design Therapeutics
- Insider Trades May Not Tell You What You Think
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Retail Stocks Investing, Explained
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Consumer Discretionary Stocks Explained
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
